Condition: KCNT1-Related Epilepsy · Sponsor: Actio Biosciences, Inc.
This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.
This description comes directly from the study's public registry record.
Actio Biosciences, Inc. · +1 (858) 679-5891 · info@actiobiosciences.com
Always discuss trial participation with your own doctor first.
| Scientia Clinical Research | Sydney, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07156201